Valuation: Mylan N.V.

Market Cap 19.03B 16.65B 15.35B 14.2B 26.96B 1,816B 27.41B 184B 72.06B 892B 71.44B 69.89B 3,090B P/E 2026 *
59.8x
P/E 2027 * 25.9x
Enterprise Value 31.22B 27.31B 25.18B 23.3B 44.22B 2,980B 44.96B 302B 118B 1,463B 117B 115B 5,068B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 2x
Free-Float
92.23%
Yield 2026 *
3.11%
Yield 2027 * 3.19%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 19.03B
+0.09%+0.25%+54.65%+169.19% 1,085B
-1.63%-1.50%+65.79%+62.70% 624B
-1.12%-4.27%+31.10%+84.44% 442B
+0.95%-0.59%+28.75%+27.65% 332B
-2.04%-9.46%+23.17%+28.57% 277B
+0.58%-2.22%+26.08%+45.81% 282B
+0.67%-1.53%-29.34%-39.37% 217B
-1.19%-2.81%+22.63%+66.30% 196B
-0.72%+2.72%+19.07%+81.19% 167B
Average +0.18%-1.86%+26.88%+58.50% 402.44B
Weighted average by Cap. +0.22%-1.06%+38.28%+85.06%

Financials

2026 *2027 *
Net sales 14.77B 12.92B 11.92B 11.03B 20.93B 1,410B 21.28B 143B 55.95B 693B 55.46B 54.26B 2,399B 15.04B 13.15B 12.13B 11.22B 21.3B 1,435B 21.66B 145B 56.95B 705B 56.45B 55.23B 2,442B
Net income 13M 11.37M 10.49M 9.7M 18.41M 1.24B 18.72M 126M 49.22M 609M 48.79M 47.74M 2.11B 498M 435M 401M 371M 705M 47.49B 717M 4.81B 1.88B 23.32B 1.87B 1.83B 80.78B
Net Debt 12.19B 10.66B 9.83B 9.1B 17.27B 1,163B 17.55B 118B 46.15B 571B 45.75B 44.76B 1,979B 11.03B 9.65B 8.9B 8.23B 15.63B 1,053B 15.89B 107B 41.77B 517B 41.41B 40.51B 1,791B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-